Xencor.com

Site Inspections

Overview & More informations

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company's proprietary XmAb® antibody engineering technology enables it to create antibodies with enhanced affinity, specificity, and potency. Xencor's lead product candidate, XmAb5871, is a monoclonal antibody that targets CD19, a protein expressed on the surface of B cells. XmAb5871 is being evaluated in a Phase 2 clinical trial for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Xencor has also developed a number of other XmAb antibody candidates that are in various stages of preclinical and clinical development. The company's technology platform has the potential to generate a wide range of antibody therapeutics for the treatment of a variety of diseases.

In addition to the information above, here are some other key facts about Xencor:

* The company was founded in 1997 and is headquartered in Monrovia, California.
* Xencor has a market capitalization of approximately $1.5 billion.
* The company's stock is traded on the Nasdaq Global Market under the symbol "XNCR."
* Xencor has a strong track record of innovation and has been recognized for its work in the field of antibody engineering.
* The company has a number of strategic partnerships with leading pharmaceutical companies, including AbbVie, Amgen, and Pfizer.

Xencor is a well-respected company with a strong track record of success. The company's proprietary XmAb antibody engineering technology has the potential to generate a wide range of antibody therapeutics for the treatment of a variety of diseases. Xencor is a company to watch in the years to come.

Domains Expiration Date Updated